<unk>  is an immunostimulatory antibody that targets signaling lymphocyte activation molecule family member 7, also known as SLAMF7. SLAMF7 is a cell surface glycoprotein that is present on myeloma cells, natural killer cells, plasma cells, and subsets of immune cells of the hematopoietic lineage.<unk>  works by activating the natural killer cells through the SLAMF7 pathway. Along with that, the SLAMF7 of the myeloma cells are targeted and flagged, for natural killer cell-mediated destruction through antibody-dependent cellular toxicity.
Elotuzumab
Pertuzumab
Idarucizumab
Gatipotuzumab
Theralizumab
Alemtuzumab
Etaracizumab
Risankizumab